NanoViricides wins DRC ACOREP clearance for Phase II NV-387 Ebola treatment trial
NNVC•DRC clearance for Phase II trial
NanoViricides secured clearance from DRC regulator ACOREP to start a Phase II trial of NV-387 oral gummies for Bundibugyo ebolavirus.
The company expects first patient dosing within weeks, citing trial preparations already underway in the Democratic Republic of Congo.
